Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: A [11C]SB207145 PET study

Molecular Psychiatry

Volumn 19, Issue 4, 2014, Pages 427-432

  Haahr, M E ^a,b   Fisher, P M ^a,b   Jensen, C G ^a,b   Frokjaer, V G ^a,b   McMahon, B ^a,b   Madsen, K ^a,b   Baare W F C ^b,c   Lehel, S ^b,d   Norremolle, A ^a   Rabiner, E A ^e,f   Knudsen, G M ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Center for Integrated Molecular Brain Imaging   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

^e Imanova Ltd   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Neuroimaging; PET; Serotonin; Serotonin 4 receptor

Indexed keywords

FLUOXETINE; NORFLUOXETINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; SB 207145 C 11; SEROTONIN 4 RECEPTOR; UNCLASSIFIED DRUG; CARBON; PIPERIDINE DERIVATIVE; SB 207145; SEROTONIN UPTAKE INHIBITOR;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RECEPTOR DENSITY; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; BRAIN; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BINDING; SCINTISCANNING; YOUNG ADULT;

ADULT; BRAIN; CARBON RADIOISOTOPES; DOUBLE-BLIND METHOD; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84897114719     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.147     Document Type: Article

References (39)

1. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006; 189: 309-316
2. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 2010; 30: 1682-1706
3. Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol 2013; 25: 1-10
4. Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol Psychiatry 2012; 17: 1254-1260
5. Pinborg LH, Feng L, Haahr ME, Gillings N, Dyssegaard A, Madsen J et al. No change in [11C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human. Synapse 2012; 66: 880-884
6. Licht CL, Marcussen AB, Wegener G, Overstreet DH, Aznar S, Knudsen GM. The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. J Neurochem 2009; 109: 1363-1374
7. Vidal R, Valdizan EM, Mostany R, Pazos A, Castro E. Long-term treatment with fluoxetine induces desensitization of 5-HT4 receptor-dependent signalling and functionality in rat brain. J Neurochem 2009; 110: 1120-1127
8. Vidal R, Valdizan EM, Vilaro MT, Pazos A, Castro E. Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats. Br J Pharmacol 2010; 161: 695-706
9. Jennings KA, Licht CL, Bruce A, Lesch KP, Knudsen GM, Sharp T. Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT4 receptor levels. Int J Neuropsychopharmacol 2011; 16: 1-9
10. Marner L, Gillings N, Madsen K, Erritzoe D, Baare WF, Svarer C et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage 2010; 50: 855-861
11. Fisher PM, Holst KK, McMahon B, Haahr ME, Madsen K, Gillings N et al. 5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [11C]SB207145 PET in humans. NeuroImage 2012; 62: 130-136
12. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531
13. Stark P, Fuller RW, Wong DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46(3 Pt 2): 7-13
14. Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999; 60: 389-394
15. Lucchelli A, Santagostino-Barbone MG, Barbieri A, Candura SM, Tonini M. The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol 1995; 114: 1017-1025
16. Haahr ME, Fisher P, Holst K, Madsen K, Jensen CG, Marner L et al. The 5-HT(4) receptor levels in hippocampus correlates inversely with memory test performance in humans. Hum Brain Mapp 2012; doi:10. 1002/hbm. 22123 (e-pub ahead of print)
17. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983; 24: 385-396
18. Forsell Y. The Major Depression Inventory versus Schedules for Clinical Assessment in Neuropsychiatry in a population sample. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 209-213
19. Rice JP, Reich T, Bucholz K, Neuman RJ, Fishman R, Rochberg N et al. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcohol Clin Exp Res 1995; 19: 1018-1023
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
21. Watts R, Spencer EP, Wood M. Quantitative analysis of multiple psychotherapeutic drugs in human serum using UPLC/MS/MS. In: Corporation W (ed). )USA, Milford, 2008
22. Olesen OV, Sibomana M, Keller SH, Andersen F, Jensen JA, Holm S et al. Spatial resolution of the HRRT PET scanner using 3D-OSEM PSF reconstruction. Nuclear Science Symposium Conference Record (NSS/MIC), 2009 IEEE (ISBN: 978-1-4244-3961-4); doi:10. 1109/NSSMIC. 2009. 5401892
23. Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med 2008; 49: 1000-1008
24. Haahr ME, Rasmussen PM, Madsen K, Marner L, Ratner C, Gillings N et al. Obesity is associated with high serotonin 4 receptor availability in the brain reward circuitry. Neuroimage 2012; 61: 884-888
25. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16: 620-633
26. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG et al. MRbased automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005; 24: 969-979
27. Marner L, Gillings N, Comley RA, Baare WF, Rabiner EA, Wilson AA et al. Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med 2009; 50: 900-908
28. Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 2010; 67: 1033-1039
29. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993; 8: 337-344
30. Madsen K, Marner L, Haahr M, Gillings N, Knudsen GM. Mass dose effects and in vivo affinity in brain PET receptor studies-a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nucl Med Biol 2011; 38: 1085-1091
31. Taylor S, Abramowitz JS, McKay D. Non-adherence and non-response in the treatment of anxiety disorders. J Anxiety Disord 2012; 26: 583-589
32. Math SB, Janardhan Reddy YC. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int J Clin Pract 2007; 61: 1188-1197
33. Charlier C, Pinto E, Ansseau M, Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000; 15: 453-459
34. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992; 584: 322-324
35. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229: 101-103
36. Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994; 33: 367-386
37. Lewis DA, Campbell MJ, Foote SL, Morrison JH. The monoaminergic innervation of primate neocortex. Hum Neurobiol 1986; 5: 181-188
38. Popa D, Cerdan J, Reperant C, Guiard BP, Guilloux JP, David DJ et al. A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur J Pharmacol 2010; 628: 83-90
39. Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL. In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 2000; 38: 460-470.